Hussain Haideri, M.D.

Resilient physician administrator, with experience of all facets of clinical care, now aspiring to advance knowledge and competency in leadership, team building and growth of operations. Talented at cohesive work force communication, teaching, social interaction, conflict resolution and community outreach. Strong interpersonal and public speaking skills, with a flair for writing.

• Member, American College of Healthcare Executives.
• Co-Editor, Whole Health Magazine at VA North Texas Healthcare.
• Chair, CME APPNA Annual Physician Meeting, Dallas, TX 2023.
• Member Quality Improvement Committee, Shawnee Mission Medical Center.
• Member, Nephrology Subcommittee, Pharmacy, therapeutic and technology Subcommittee, Providence Hospital, Kansas City, KS.
• Member, Cardiovascular Outcome Improvement Committee, Shawnee Mission Medical Center. Shawnee, Kansas, 2014-2017.
• Resident Representative; Ethics Committee, Illinois Masonic Hospital, Chicago, IL 1995-1996.
• Ex-Medical Director, Venture Research Group, Mission, Kansas.
• Guest Lecturer, Renal, fluid and electrolyte physiology, , University of Wisconsin at Madison, School of Pharmacy, 1997.
• Podcast Host for Veterans on Whole Health and related topics.
• Host Radio Program, Radio Azad, Dallas, TX
• CME Presentation Faculty, International meetings at Shiraz, Iran and Beijing, China.

• Research. Presentations and Clinical Trail experience
• Poster presentation, Effect   of nephrectomy, post transplant for control of blood pressure, Chicago 1997, Am.   Soc of Transplant.
• HIV patients and proteinuria, timed urine collection   versus spot protein to creatinine ratio, Cook County Hospital, 1996.
• Multi-center, randomized, open-label trial to compare : Efficacy of 12 weeks of treatment with   Aracabose 100 mg, to Aracabose 50 mg, as add-on RX in   patients with type II diabetes mellitus, inadequately controlled with   Metformin monotherapy. 2006.
• Randomized, double blind phase 3 study of efficacy and   safety of PPI in subjects requiring NSAID treatment. 2007.
• Randomized, multicenter, double blinded, placebo   controlled trial, dose range, parallel design, Phase 2 of Oral for patients with Linzess for Irritable Bowel syndrome.
• Randomized, DB, parallel group , Phase 3 efficacy and safety trail of Warfarin and ASA compared to Clopidogrel, to reduce upper GI bleed. 2008.
• Open label, randomized active controlled multi center   Phase II, dose finding study of Label XX to lower serum phosphate levels in   patients with CKD on maintenance hemodialysis. 2010.
• A randomized, DB,placebo controlled phase 2 trial of Rosuvastatin   compared to ATORVASTATIN for myalgia incidence in hyperlipidemia RX. 2011.

Philately, Public Speaking., Poetry, International Acid burn victim Relief team Coordinator, Interfaith Leadership, Youth Mentoring and Development.